![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
KJ Chang, GC Rigdon, JL Howard and RW McNutt
Division of Cell Biology, Burroughs Wellcome Co., Research Triangle Park, North Carolina.
Four different opioid receptor binding assays and three different isolated tissue studies were used to screen for delta receptor- selective nonpeptidic compounds. (+/-)-4-((alpha-R*)-alpha-((2S*,5R*)-4- Allyl-2,5- dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N,N- diethylbenzamide (BW373U86) was a potent delta receptor-selective ligand in receptor binding assays. The Ki values were 1.8 +/- 0.4, 15 +/- 3, 85 +/- 4 and 34 +/- 3 nM for delta, mu, epsilon and kappa receptor binding sites, respectively. BW373U86 inhibited electrically evoked muscle contraction of mouse vas deferens with an ED50 value of 0.2 +/- 0.06 nM. This inhibitory effect of BW373U86 was antagonized by the delta receptor-selective antagonist naltrindole in a competitive manner: the Schild plot indicated a slope of 1 and a pA2 value of 9.43 (Ke = 3.7 x 10(-10) M), which is consistent with the high affinity of naltrindole in delta receptors. BW373U86 did not interact significantly with other receptors. BW373U86 inhibited the acoustic startle reflex after subcutaneous administration from 0.2- to 2-mg/kg doses in rats, and this inhibition was blocked by naltrindole. BW373U86 also induced a dose-dependent increase of locomotor activity in rats at similar doses. This effect was inhibited by naltrindole. These data suggest that BW373U86 is a potent and selective nonpeptidic delta agonist, and it elicits distinct in vivo pharmacological activities.
This article has been cited by other articles:
|
|
 |
|
  H. Xie, J. H. Woods, J. R. Traynor, and M.-C. Ko The Spinal Antinociceptive Effects of Endomorphins in Rats: Behavioral and G Protein Functional Studies Anesth. Analg., June 1, 2008; 106(6): 1873 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Codd, J. R. Carson, R. W. Colburn, S. L. Dax, D. Desai-Krieger, R. P. Martinez, L. A. McKown, L. A. Neilson, P. M. Pitis, P. L. Stahle, et al. The Novel, Orally Active, Delta Opioid RWJ-394674 Is Biotransformed to the Potent Mu Opioid RWJ-413216 J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1273 - 1279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Michael. J. Watson, J. D. S. Holt, S. J. O'Neill, K. Wei, W. Pendergast, G. J. Gross, P. J. Gengo, and K.-J. Chang ARD-353 [4-((2R,5S)-4-(R)-(4-Diethylcarbamoylphenyl)(3-hydroxyphenyl)methyl)-2,5-dimethylpiperazin-1-ylmethyl)benzoic Acid], A Novel Nonpeptide {delta} Receptor Agonist, Reduces Myocardial Infarct Size without Central Effects J. Pharmacol. Exp. Ther., January 1, 2006; 316(1): 423 - 430. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. D. S. Holt, M. J. Watson, J. P. Chang, S. J. O'Neill, K. Wei, W. Pendergast, P. J. Gengo, and K.-J. Chang DPI-221 [4-(({alpha}-S)-{alpha}-((2S,5R)-2,5-Dimethyl-4-(3-fluorobenzyl)-1-piperazinyl)benzyl)-N,N-diethylbenzamide]: A Novel Nonpeptide {delta} Receptor Agonist Producing Increased Micturition Interval in Normal Rats J. Pharmacol. Exp. Ther., November 1, 2005; 315(2): 601 - 608. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Gengo, H. O. Pettit, S. J. O'Neill, Y. F. Su, R. McNutt, and K.-J. Chang DPI-3290 [(+)-3-(({alpha}-R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. II. A Mixed Opioid Agonist with Potent Antinociceptive Activity and Limited Effects on Respiratory Function J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1227 - 1233. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Gengo, H. O. Pettit, S. J. O'Neill, K. Wei, R. McNutt, M. J. Bishop, and K.-J. Chang DPI-3290 [(+)-3-(({alpha}-R)-{alpha}-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-hydroxybenzyl)-N-(3-fluorophenyl)-N-methylbenzamide]. I. A Mixed Opioid Agonist with Potent Antinociceptive Activity J. Pharmacol. Exp. Ther., December 1, 2003; 307(3): 1221 - 1226. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. I. Svensson, Y. Rew, S. Malkmus, P. W. Schiller, J. P. Taulane, M. Goodman, and T. L. Yaksh Systemic and Spinal Analgesic Activity of a {delta}-Opioid-Selective Lanthionine Enkephalin Analog J. Pharmacol. Exp. Ther., February 1, 2003; 304(2): 827 - 832. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Broom, J. F. Nitsche, J. E. Pintar, K. C. Rice, J. H. Woods, and J. R. Traynor Comparison of Receptor Mechanisms and Efficacy Requirements for delta -Agonist-Induced Convulsive Activity and Antinociception in Mice J. Pharmacol. Exp. Ther., November 1, 2002; 303(2): 723 - 729. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Kodani, Y.-T. Xuan, K. Shinmura, H. Takano, X.-L. Tang, and R. Bolli delta -Opioid receptor-induced late preconditioning is mediated by cyclooxygenase-2 in conscious rabbits Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1943 - H1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Zhang, B. C. McPherson, H. Liu, T. Baman, S. S. McPherson, P. Rock, and Z. Yao Role of Nitric-Oxide Synthase, Free Radicals, and Protein Kinase C delta in Opioid-Induced Cardioprotection J. Pharmacol. Exp. Ther., June 1, 2002; 301(3): 1012 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gyires and A. Z. Rónai Supraspinal delta - and {micro}-Opioid Receptors Mediate Gastric Mucosal Protection in the Rat J. Pharmacol. Exp. Ther., June 1, 2001; 297(3): 1010 - 1015. [Abstract] [Full Text]
|
|
|
|
|
|
M. R. Brandt, M. S. Furness, N. K. Mello, K. C. Rice, and S. S. Negus Antinociceptive Effects of {delta}-Opioid Agonists in Rhesus Monkeys: Effects on Chemically Induced Thermal Hypersensitivity J. Pharmacol. Exp. Ther., March 1, 2001; 296(3): 939 - 946. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. C. McPherson and Z. Yao Morphine Mimics Preconditioning via Free Radical Signals and Mitochondrial KATP Channels in Myocytes Circulation, January 16, 2001; 103(2): 290 - 295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. C. Broom, L. Guo, A. Coop, S. M. Husbands, J. W. Lewis, J. H. Woods, and J. R. Traynor BU48: A Novel Buprenorphine Analog That Exhibits delta -Opioid-Mediated Convulsions but Not delta -Opioid-Mediated Antinociception in Mice J. Pharmacol. Exp. Ther., September 1, 2000; 294(3): 1195 - 1200. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. A. J. Becker, A. Wallace, A. Garzon, P. Ingallinella, E. Bianchi, R. Cortese, F. Simonin, B. L. Kieffer, and A. Pessi Ligands for kappa -Opioid and ORL1 Receptors Identified from a Conformationally Constrained Peptide Combinatorial Library J. Biol. Chem., September 24, 1999; 274(39): 27513 - 27522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Brandt, S. S. Negus, N. K. Mello, M. S. Furness, X. Zhang, and K. C. Rice Discriminative Stimulus Effects of the Nonpeptidic delta -Opioid Agonist SNC80 in Rhesus Monkeys J. Pharmacol. Exp. Ther., September 1, 1999; 290(3): 1157 - 1164. [Abstract] [Full Text]
|
|
|
|
 |
|
 R. M. Quock, T. H. Burkey, E. Varga, Y. Hosohata, K. Hosohata, S. M. Cowell, C. A. Slate, F. J. Ehlert, W. R. Roeske, and H. I. Yamamura The delta -Opioid Receptor: Molecular Pharmacology, Signal Transduction, and the Determination of Drug Efficacy Pharmacol. Rev., September 1, 1999; 51(3): 503 - 532. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-F. Su, R. W. McNutt, and K.-J. Chang Delta-Opioid Ligands Reverse Alfentanil-Induced Respiratory Depression but Not Antinociception J. Pharmacol. Exp. Ther., December 1, 1998; 287(3): 815 - 823. [Abstract] [Full Text]
|
|
|
|
|
|
S. F. Sezen, V. A. Kenigs, and D. R. Kapusta Renal Excretory Responses Produced by the Delta Opioid Agonist, BW373U86, in Conscious Rats J. Pharmacol. Exp. Ther., October 1, 1998; 287(1): 238 - 245. [Abstract] [Full Text]
|
|
|
|
|
|
J. E. Nowak, R. Gomez-Flores, S. N. Calderon, K. C. Rice, and R. J. Weber Rat Natural Killer Cell, T Cell and Macrophage Functions after Intracerebroventricular Injection of SNC 80 J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 931 - 937. [Abstract] [Full Text]
|
|
|
|
|
|
S. S. Negus, M. B. Gatch, N. K. Mello, X. Zhang, and K. Rice Behavioral Effects of the Delta-Selective Opioid Agonist SNC80 and Related Compounds in Rhesus Monkeys J. Pharmacol. Exp. Ther., July 1, 1998; 286(1): 362 - 375. [Abstract] [Full Text]
|
|
|
|
|
|
M. J. Picker Discriminative Stimulus Effects of the Mixed-Opioid Agonist/Antagonist Dezocine: Cross-Substitution by Mu and Delta Opioid Agonists J. Pharmacol. Exp. Ther., December 1, 1997; 283(3): 1009 - 1017. [Abstract] [Full Text]
|
|
|
|
|
|
S. J. O'Neill, M. A. Collins, H. O. Pettit, R. W. McNutt, and K.-J. Chang Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 271 - 277. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
